Formycon AG (ETR:FYB)
23.25
+0.10 (0.43%)
May 5, 2025, 5:35 PM CET
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€278,696
Profits / Employee
€502,688
Market Cap
408.76M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Merck KGaA | 59,020 |
Siemens Healthineers AG | 72,000 |
Fresenius SE & Co. KGaA | 176,486 |
Bayer Aktiengesellschaft | 90,587 |
Sartorius Aktiengesellschaft | 13,528 |
Fresenius Medical Care AG | 111,513 |
Carl Zeiss Meditec AG | 5,730 |
Fielmann Group AG | 23,412 |
Formycon AG News
- 21 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 5 weeks ago - Formycon's 2024: Financial Success & Market Growth - Wallstreet:Online
- 5 weeks ago - EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position - Wallstreet:Online
- 6 weeks ago - EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025 - Wallstreet:Online
- 2 months ago - EQS-News: FYB202/Otulfi (ustekinumab-aauz), a biosimilar to Stelara, launched in the United States and the European Union - Wallstreet:Online
- 2 months ago - EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea, under the brand name AHZANTIVE - Wallstreet:Online
- 2 months ago - EQS-DD: Formycon AG: Dr. Andreas Seidl, buy - Wallstreet:Online
- 2 months ago - EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin - Wallstreet:Online